Pharmaceutical CAS 147245-92-9 Glatiramer Acetate Materials Glatiramer Acetate Purity Peptides Glatiramer Acetate

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Model NO.: D-sung Glatiramer Acetate
• Product Name: Glatiramer Acetate
• Name: Glatiramer Acetate Powder
• Appearance: White Powder
• Color: White
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 147245-92-9
• Mf: C25h45n5o13
• MW: 623.657
• Einecs: 814-981-5
• Boiling Point: 385.2°cat760mmhg
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 500kg/Month

Product Description

Pharmaceutical CAS 147245-92-9 Glatiramer Acetate Materials Glatiramer Acetate Purity Peptides Glatiramer Acetate

Product Description

Product Details

Product name	Glatiramer Acetate
Appearance	White powder
CAS NO.	147245-92-9
MF	C25H45N5O13
MW	623.657

Glatiramer acetate (also known as Copolymer 1, Cop-1, or Copaxone - as marketed by Teva Pharmaceuticals) is animmunomodulator drug currently used to treat multiple sclerosis. Glatiramer acetate is a random polymer of four amino acids found inmyelin basic protein, namely glutamic acid, lysine, alanine, and tyrosine, and may work as a decoy for the immune system. 
Although the clinical definition of multiple sclerosis requires two or more episodes of symptoms and signs, glatiramer acetate is approved for treatment after single episodes. Glatiramer acetate is also used to treat relapsing-remitting multiple sclerosis. Glatiramer acetate is administered by subcutaneous injection.

Application&Function

Glatiramer acetate is approved by the Food and Drug Administration (FDA) for reducing the frequency of relapses, but not for reducing the progression of disability. Observational studies, but not randomized controlled trials, suggest that Glatiramer acetate may reduce progression of disability.

Specification